February 12, 2026 04:22 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues
Image: Youtube Screen grab

Supreme Court lifts ban on sale of Saridon and two other drugs

| @indiablooms | Sep 17, 2018, at 02:11 pm

New Delhi, Sept 17 (IBNS): Days after the Centre's ban on 328 combinationdrugs, the Supreme Court on Monday allowed the sale of Saridon and two other drugs for now, media reports said.

The top court passed the order after a petition against the ban was filed by the drug makers.

Around 6,000 drug brands including Saridon (painkiller), Panderm (skin cream), Lupidiclox (antibiotic), Corex (cough syrup) were expected to be affected by this ban.

In December 2017, the Supreme Court asked Drugs Technical Advisory Board (DTAB) to intervene in the matter.

The DTAB eventually said there was no therapeutic evidence that the ingredients in about 328 of these FDCs cause any harm to people.

The All India Drug Action Network sought the banning of the drugs which were not part of the DTAB report, as these itself accounted for about Rs 2,500 crore of the pharmaceutical market.


 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.